Evaluation of effect of scopolamine on stages of active avoidance learning in rats by Das, A. et al.
      SCOPOLAMINE AND ACTIVE AVOIDANCE
Indian Journal of Pharmacology 2003;  35:   47-50        SHORT COMMUNICATION
Correspondence: C. Nath
 e-mail: cnathcdri@rediffmail.com
ABSTRACT
EVALUATION OF EFFECT OF SCOPOLAMINE ON STAGES OF ACTIVE
AVOIDANCE LEARNING IN RATS
A. DAS, M. DIKSHIT, H.K. SINGH, C. NATH*
Division of Pharmacology, Central Drug Research Institute, Lucknow - 226 001.
Manuscript Received: 19.3.2002 Revised: 20.7.2002 Accepted: 25.8.2002
Objective: To investigate the effect of scopolamine administered at different stages of learning and
memory process in active avoidance task in rats.
Methods: Adult male Sprague-Dawley rats were trained on active avoidance task. Each animal
received a daily session of 15 trials for 5 days i.e., a maximum of 75 trials. Scopolamine (3 mg/kg, i.p)
was administered at different time points according to acquisition, consolidation and recall of active
avoidance learning in the three groups (n=8). Increase in avoidance response on 5th session as
compared to 1st session was taken as criteria of learning and failure of learning was considered as
dementia.
Results: There was a significant increase in the avoidance response on 5th session as compared to
1st session in the control group. Among scopolamine treated groups, most marked dementia was
observed in the group that received scopolamine after the last trial of 1st session.
Conclusion: Results of this study show that scopolamine preferentially affects acquisition and
consolidation as compared to recall of memory in the learning process.
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INTRODUCTION
On the basis of experimental as well as clinical evi-
dences, central cholinergic system is considered as
the most important neurotransmitter involved in regu-
lation of cognitive functions1-2. Cholinergic neuronal
loss along with abnormal proteins, β-amyloid and tau,
and associated impaired cognitive functions are the
major features of senile dementia of Alzheimer
type3-4. Blockade of central muscarinic acetylcholine
receptor disrupts learning and memory functions in
animals and human beings5. Anticholinergic drug
(muscarinic blocker) such as scopolamine has been
in use as potent dementic agent. It induces cognitive
deficit in young volunteers which is qualitatively simi-
lar to that occurring naturally in aged subjects when
tested on the same clinical battery. One such deficit
was loss of memory in young subjects for recent (but
not immediate) events6. Similarly, scopolamine in-
jected into young monkeys caused memory deficits
similar to those occurring naturally in aged monkeys7.
In our earlier studies we have shown administration
of scopolamine prior to first trial (acquisition) induced
deficit in passive avoidance learning8. In the process
of learning and memory, three important stages have
been suggested viz., acquisition, consolidation and
recall of the learned task9. Inspite of extensive use
of scopolamine as dementic agent in experimental
studies, it is still not clearly defined as to which of
the stage of learning and memory process is affected
more by it in experimental models. Therefore, the
present study was performed to investigate the ef-
fect of scopolamine administered at different stages
of active avoidance learning in rats.
MATERIALS AND METHODS
Animals: Study was conducted on adult male
Sprague-Dawley rats of 3-4 months (wt. 175-200 g).
The animals were kept in polyacrylic cages
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(38 x 23 x 10 cm) with 1-2 animals per cage and
maintained under standard housing conditions (Room
temperature 24-27oC and humidity 60-65%) with 12 h
light and dark cycle. The food in form of dry pellets
and water were available ad libitum.
The animals were procured from the Laboratory Ani-
mal Services Division of Central Drug Research In-
stitute. The animal experiments were performed ac-
cording to internationally followed ethical standards
and approved by the research ethics committee of
Central Drug Research Institute.
Active avoidance training: The animals were
trained on Active Avoidance Task in a computerized
shuttle box (Columbus Instruments, Ohio, USA) pro-
vided with a software program PACS 30. Rat is placed
in a compartment separated from the other one by a
guillotine door in the shuttle box. After an exploration
period of 2 min the guillotine door automatically opens.
Thereafter, the trial starts. In each trial the animal is
subjected after 30 s first to a light followed by sound
stimulus at intensity of 8 (scale of 0 - off and 10 -
maximum, provided in the PACS 30 software) for 10
s each in a total trial period of 1 min. Immediately
after the sound stimulus, the rat receives a single
low intensity foot shock  (0.5 mA; 10 s) through the
floor grid if it does not transfer to the other compart-
ment (shock free). Infrared sensors monitor the trans-
fer time from one compartment to another, which is
recorded as avoid (after the stimulus either light alone
or both light and sound) and escape (after the foot
shock) response. Each animal received a daily ses-
sion of 15 trials with an inter-trial duration of 15 s for
5 days i.e., a maximum of 75 trials. The rats were
evaluated for learning and memory functions on the
basis of their performance in the last session i.e., in
the 5th session. The criterion for improved cognitive
activity was taken as significant increase in the avoid-
ance response on 5th session (retention) as compared
to 1st session (training).
Scopolamine administration: The animals were
divided into four different groups (n=8). Scopolamine
(3 mg/kg, i.p) was administered at different time peri-
ods in the three groups as follows:
Group I - no scopolamine, (control),
Group II - scopolamine was administered 5 min prior
to 1st Trial on 1st session (Training session),
Group III - scopolamine was administered 5 min after
the 15th (i.e., last) trial on 1st session (Training ses-
sion), and
Group IV - scopolamine was administered 5 min prior
to the 1st trial on the last session i.e., 5th session
(Retention test).
Dementic effect of scopolamine was evaluated
on the basis of significant decrease in number of
avoidance response in the treated groups as com-
pared to that of control group in the last session i.e.,
5th session.
Statistical analysis: Mean values and standard er-
ror (SE) of mean were calculated for the numbers of
avoid response. The significance of difference be-
tween the values of control and scopolamine treated
groups for each session was determined by ANOVA
(one-way) followed by Dunnett's test. The difference
between the values of 1st session (training) and 5th
session (retention test) of the same group was ana-
lysed by Student's paired ' t ' test. The data of per-
cent change was analyzed by test of proportion, z
test. P values < 0.05 were considered significant.
Chemicals: Scopolamine hydrobromide was pur-
chased from Sigma Chemicals, USA.
RESULTS
There was a significant (p<0.001) increase in avoid-
ance response on 5th session (9.0±1.29) as compared
to 1st session (4.75±0.25) in the control group
(group I) whereas the scopolamine treated groups,
(group II-IV) did not show any significant increase in
the avoidance responses on 5th session as compared
to 1st session (Table 1).
Group II (4.25±0.75) and III (3.50±1.32) i.e., the one
in which scopolamine was administered prior to first
trial and after the last trial, respectively on 1st ses-
sion showed a significant (p<0.01) decrease in avoid-
ance response as compared to the control group
(9.0±1.29) on 5th session (Table 1). In the scopolamine
treated group II and III, there was 6 and 48 % de-
crease in avoidance response on 5th session from 1st
session respectively, whereas scopolamine treated
group IV and control (group I) group showed a 35  and
89 % increase in percent change in avoidance re-
sponse on 5th session as compared to 1st session,
respectively (Figure 1).
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Table 1. Showing the number (mean±SEM) of avoidance responses in the control (group I) and scopolamine (scop) treated
(group II - IV) groups (n=8) on each session of active avoidance training.
Sessions
Groups
1st 2nd 3rd 4th 5th
I (control) 4.75 ± 0.25 3.50 ± 1.04 4.75 ± 1.60 5.20 ± 1.08 9.0 ± 1.29*
II (scop) 4.50 ± 0.50 4.00 ± 0.71 4.25 ± 1.25 4.50 ± 0.50 4.25 ± 0.75@
III (scop) 6.75 ± 1.11 3.75 ± 1.43 3.00 ± 0.71 3.50 ± 1.19 3.50 ± 1.32@
IV (scop) 4.25 ± 1.11 4.00 ± 1.08 4.25 ± 1.11 5.75 ± 1.18 5.75 ± 1.50
One-way ANOVA
P >0.05 >0.05 >0.05 >0.05 <0.05
F 1.887 0.048 0.381 0.330 3.826
df 3, 28 3, 28 3, 28 3, 28 3, 28
@P<0.001, significant difference from the control in 5th session (retention) by Dunnett's test, and *P<0.01, significant difference
between 1st session (training) and 5th session (retention) of the same group by Student's paired ' t ' test.
Figure 1. The percent change in avoidance response on 5th session from 1st session in control (group I) and scopolamine treated
(group II-IV) groups (n=8). *P<0.01, **P<0.001, significant difference from the control group and @P<0.01, significantly
different from scopolamine treated group IV (test of proportion [z test]).
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DISCUSSION
Avoidance response has been suggested to reflect
cognitive functions10 and was investigated for its sus-
ceptibility to scopolamine treatment in rats. The dif-
ferent time points of scopolamine administration em-
ployed in the present study were based on the stages
of learning and memory. Scopolamine treatment was
aimed in group II for acquisition, group III for consoli-
dation and group IV for recall of the learned task (avoid-
ance response) in active avoidance test. Although
there was a general decrease in performance in the
active avoidance learning in the scopolamine treated
groups as compared to control group the effect was
more apparent when scopolamine was administered
on the 1st session i.e., group II (5 min prior to 1st Trial
on 1st session) and III (5 min after the 15th i.e., last
trial on 1st session) as compared to its administration
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on its last session i.e., 5th session in group IV (5 min
prior to the 1st trial on the last session i.e., 5th ses-
sion). Thus the acquisition and consolidation proc-
ess of learned task rather than the  recall is more
susceptible to the effect of scopolamine.
There is also substantial clinical evidence that
muscarinic receptor blockade results into disruptions
of behavioral inhibition, working (short term) memory,
retrieval from reference (long term) memory, atten-
tion, decisional processes, movement and strategy
selection, and altered sensory processing11. Thus
central cholinergic neurons are important in the ac-
quisition and post-acquisition (consolidation) perform-
ance of a variety of learned behaviors11. The dementic
effects of scopolamine observed in the present study
are in concurrence with those observed in clinical situ-
ations. Therefore, the preferential effect of scopola-
mine on acquisition and consolidation of memory in
the learning process, suggest that the time of admin-
istration of scopolamine is an important factor in the
study of its effect on learning and memory.
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